Safety and Tolerability of Everolimus as second-line Treatment on poorly differentiated neuroendocrine carcinoma/ neuroendocrine carcinoma G3 according to WHO 2010 and neuroendocrine Tumor G3 - an investigator initiated Phase II study
(Neuroendokriner Tumor, NET, Hormone, Tumormarker, Chromogranin A, CgA, Leber, Darm, Pankreas, Bauchspeicheldrüse)
Everolimus (Afinitor®) should be administered orally once daily at the same time every day, consistently either with or without food.
